Malaria is the world's leading parasitic endemic and the major cause of morbidity and mortality in Côte d'Ivoire. The aim of this study was to analyse the clinical aspects and evaluate a kit’s performance (NovaLisa® Malaria) against a panel of antigens (AMA1, GLURP, CSP and Schizont Extract) to determine the antigen used in diagnosing malaria serology in Côte d’Ivoire. A retrospective study was carried out on patients requesting malaria serological test. The ELISA technique and an antigen panel was respectively used for the multi-antigen approach and to measure the proportion of responders from 28 samples. 345 samples were assayed, with a positive rate of 92.49% (319/345) revealed by the malaria serology test with a mean concentration of 50.1 NTU, 6.38% (22/345) of negativity with a mean concentration of 5.96 NTU and 1.16% (4/345) in the doubtful zone (16.26 NTU). Mean concentration of prescriptions for cervical adenopathy was 73.12 NTU. The antigen panel seroprevalence was 35.72; 50; 64.28 and 78.5% respectively for AMA1, CSP, GLURP and schizont extract for negative samples and the proportion of responders was significant (p = 0.003) for schizont extract. The seroprevalence for the 28 samples was 60.7% for AMA1 and 89.29% for schizont extract. The proportions of responders to CSP (p = 0.008), GLURP (p < 0.001) and schizont extract (p < 0.001) antigens were significantly higher than those of non-responders. GLURP antigen and schizont extract could be used for diagnosing malaria serology in Côte d'Ivoire.
Key words: Malaria, Plasmodium falciparum, antigen, serodiagnosis.
Copyright © 2022 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0